Shanghai Junshi Bioscience Co., Ltd.

9 in Phase 3

Quick facts

Phase 3 pipeline

Bendamustine or gemcitabine · Oncology
This is a combination of two chemotherapy agents: bendamustine, which alkylates DNA and disrupts cell division, and gemcitabine, which inhibits ribonucleotide reductase and gets incorporated into DNA to cause chain termination.
Cisplatin for Injection / Carboplatin Injection · Oncology
Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and cause cross-linking, leading to cell death.
JS002 · Oncology
JS002 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses.
JS004 in combination with toripalimab · Oncology
JS004 is a CTLA-4 inhibitor that blocks immune checkpoint signaling, and when combined with toripalimab (a PD-1 inhibitor), it provides dual checkpoint blockade to enhance anti-tumor immune responses.
JS107 for Injection · Oncology
JS107 is a monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the brakes on T-cell activation.
Oxaliplatin for injection · Oncology
Oxaliplatin works by interfering with DNA replication in cancer cells, leading to cell death.
Placebo for Tifcemalimab
A placebo control arm that provides no active therapeutic effect, used as a comparator in clinical trials of Tifcemalimab.
Placebo for toripalimab · Oncology
Placebo is an inert substance with no active pharmacological mechanism.
Tifcemalimab injection · Oncology
Tifcemalimab injection is a monoclonal antibody that targets the PD-1 receptor.

Phase 2 pipeline

JS005
JS203 combined with lenalidomide · Oncology
JS203 is a PD-1 inhibitor
JS207
JS207 in combination with 9MW2821
JS212

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: